Proton FLASH radiotherapy enhances control of triple-negative breast cancer through STING-IRF3 and CD8+ T-cell immunity

Radiation therapy is a cornerstone of modern cancer treatment, using powerful beams of energy to destroy malignant cells. For decades, the primary goal has been to deliver enough radiation to kill the tumor while sparing the healthy tissue surrounding it. This balance is often difficult to achieve because the same energy that destroys cancer can also damage nearby organs, limiting how much radiation doctors can safely give. Recently, a new approach called FLASH radiotherapy has emerged. Instead of delivering radiation slowly over several minutes, FLASH delivers the entire dose in a fraction of a second. Early studies have shown that this ultra-fast delivery can protect healthy tissue from damage, but scientists have been unsure if it also changes how the treatment affects the tumor itself. Specifically, it was not known whether this speed could help the body's own immune system recognize and fight the cancer more effectively.

Researchers at the University of Pennsylvania and Institut Curie set out to answer this question using a particularly aggressive form of breast cancer known as triple-negative breast cancer. This type of cancer is difficult to treat because it lacks the specific receptors that many other drugs target, and it often returns after treatment. The team used mice that had been implanted with human-like triple-negative breast tumors to compare two types of proton radiation. Protons are tiny particles that can be precisely aimed at a tumor. In one group, the radiation was delivered at a standard speed, similar to what patients receive today. In the other group, the exact same amount of radiation was delivered at a FLASH speed, thousands of times faster. The researchers wanted to see if the speed of delivery, rather than just the total amount of energy, could change the outcome for the cancer.

The results showed that the speed of the radiation mattered significantly. The mice treated with the ultra-fast FLASH proton therapy saw their tumors shrink more and grow back more slowly than those treated with the standard-speed radiation. In some cases, the tumors disappeared completely and did not return, a result that was much more common with the FLASH treatment. This effect was most pronounced in one specific type of tumor model, where the FLASH treatment also reduced the number of cancer cells that spread to the lungs, a common and dangerous complication of this disease. The researchers found that this improved control was not just a direct result of the radiation burning the cells, but rather a change in how the body's immune system responded.

When the scientists looked inside the tumors, they discovered that the FLASH treatment triggered a faster and stronger alarm system within the cancer cells. This alarm, known as the STING pathway, acts like a smoke detector for damaged DNA. When the FLASH radiation hit the tumor, it caused this alarm to sound sooner and louder than the standard radiation did. This early signal led to a surge in chemical messengers called interferons, which act as a call to arms for the immune system. Consequently, the tumors treated with FLASH attracted a much larger number of CD8+ T cells, which are specialized white blood cells trained to hunt down and destroy cancer. These cells are the body's elite soldiers against cancer, and their increased presence inside the tumor was directly linked to the better outcomes.

To prove that these immune cells were the key to the success, the researchers performed a critical test. They treated a new group of mice with the FLASH radiation but blocked their CD8+ T cells, effectively disarming their immune system. In these mice, the advantage of the FLASH treatment vanished; the tumors grew just as fast as they did with the standard radiation. This confirmed that the speed of the radiation was not just killing cells faster, but was actively recruiting the immune system to do the heavy lifting. Furthermore, when the team combined the FLASH radiation with immunotherapy drugs designed to boost the immune system, the tumors shrank even faster and more completely than with standard radiation. The mice that survived this combined treatment developed a lasting memory of the cancer, meaning their immune systems could recognize and reject the disease if it ever tried to return.

The study suggests that the speed at which radiation is delivered is a powerful factor in how well it works, independent of the total dose given. By delivering the radiation in a flash, the treatment appears to create a more favorable environment for the immune system to attack the tumor, while still sparing healthy tissue. This finding offers a new way to think about cancer treatment, where the timing of the dose is just as important as the dose itself. While these results were observed in mice, they provide a strong biological reason to explore whether ultra-fast radiation could improve outcomes for patients with difficult-to-treat cancers, potentially turning a local treatment into a systemic cure that engages the body's own defenses.